

论著

前列地尔Lipo-PGE₁ 1干预肝脏血流灌注的实验研究

李家平¹,周奇²,王海林³,谭国胜¹,陈伟¹,杨建勇^{1△}

1中山大学附属第一医院介入放射科, 广东 广州 510080; 2中山大学附属第一医院黄埔院区外科一区, 广东 广州 510700; 3广州市第一人民医院放射科, 广东 广州 510045

收稿日期 2008-4-30 修回日期 2008-9-10 网络版发布日期 2009-2-22 接受日期 2008-9-10

摘要 目的: 探讨前列地尔脂微球(liposome prostaglandin E₁,Lipo-PGE₁) 不同用药时间和途径对肝脏血流灌注的作用机制。

方法: 选取健康成年犬12只, 经左小隐静脉注射Lipo-PGE₁₁ μg/kg, 速度均为0.05 μg · kg⁻¹ · min⁻¹。分别于0 min、5 min、15 min、30 min后行肝脏CT灌注成像(computed tomography perfusion imaging, CTPI)扫描, 计算肝动脉灌注量(hepatic arterial perfusion,HAP)、门静脉灌注量(portal vein perfusion,PVP)、总肝灌注量(total liver perfusion,TLP), 对照分析不同时间Lipo-PGE₁对肝脏血流灌注的影响。选取健康成年犬24只, 随机平均分成4组: 对照组、外周静脉用药组、肝动脉组、肠系膜上动脉组。Lipo-PGE₁的用药量均为1 μg/kg、用药速度均为0.05 μg · kg⁻¹ · min⁻¹, 0.9%生理盐水用量为20 mL。各组用药5 min后行肝脏CTPI, 比较分析不同途径给予Lipo-PGE₁对肝脏血流灌注的影响。

结果: 经外周静脉注射Lipo-PGE₁ 10 min、5 min、15 min、30 min后CTPI测量的HAP(mL · min⁻¹ · mL⁻¹)分别为: 0.22 ± 0.65、0.24 ± 0.65、0.22 ± 0.69、0.22 ± 0.06; PVP (mL · min⁻¹ · mL⁻¹): 1.22 ± 0.40、1.88 ± 0.59、1.55 ± 0.55、1.29 ± 0.57; TLP (mL · min⁻¹ · mL⁻¹)分别为: 1.44 ± 0.42、2.12 ± 0.61、1.77 ± 0.56、1.51 ± 0.58。方差分析显示HAP组间比较无显著差异(F=0.249, P>0.05), 而PVP、TLP组间比较有显著差异(F=3.812, P<0.05)、(F=3.805, P<0.05)。5 min组PVP、TLP增加最为显著, 15 min、30 min时两者仍处于高值水平。对照组和外周静脉组、肝动脉组、肠系膜上动脉组的HAP (mL · min⁻¹ · mL⁻¹)分别为: 0.22 ± 0.06、0.24 ± 0.06、0.31 ± 0.07、0.26 ± 0.05; PVP (mL · min⁻¹ · mL⁻¹)分别为1.28 ± 0.38、2.33 ± 0.41、2.37 ± 0.55、2.83 ± 0.94; TLP (mL · min⁻¹ · mL⁻¹)分别为: 1.50 ± 0.40、2.57 ± 0.42、2.67 ± 0.58、3.09 ± 0.94。方差分析显示HAP组间比较无显著差异(F=2.248, P>0.05), 而PVP、TLP组间比较有显著差异(F=6.892, P<0.01)、(F=7.802, P<0.01)。经肠系膜上动脉给药较其它途径给药PVP、TLP增加趋势更为显著。

结论: Lipo-PGE₁能显著增强肝脏血流灌注, 且主要影响门静脉灌注分量, 介入技术可为快速改善肝血流灌注提供有效途径。

关键词 肝 灌注 前列地尔 介入技术 脂微球-PGE1

分类号 R364.1

Intervention of Lipo-PGE₁ on liver blood perfusion by different time and medication: a empirical study

LI Jia-ping¹,ZHOU Qi²,WANG Hai-ling³,TAN Guo-sheng¹,CHEN Wei¹,YANG Jian-yong¹

1Department of Interventional Radiology,The First Affiliated Hospital of Sun Yat-sen University,Guangzhou 510080,China;2The First Surgery Department of Huangpu Branch,The First Affiliated Hospital of Sun Yat-sen University,Guangzhou 510700,China;3Department of Radiology,The First People Hospital of Guangzhou City,Guangzhou 510045,China.E-mail:jpli3s@medmail.com.cn

Abstract

AIM: To explore the effect and mechanism of liposome prostaglandin E₁(Lipo-PGE₁) on liver blood perfusion by different time and medication.
METHODS: Twelve healthy adult dogs were injected with Lipo-PGE₁₁ μg/kg via left small saphenous vein at speed of 0.05 μg · kg⁻¹ · min⁻¹.Liver computed tomography perfusion imaging (CTPI) was performed on 0,5,15 and 30 min,and the

扩展功能

本文信息

- ▶ [Supporting info](#)
- ▶ [PDF\(609KB\)](#)
- ▶ [\[HTML全文\]\(0KB\)](#)

参考文献

服务与反馈

- ▶ [把本文推荐给朋友](#)
- ▶ [加入我的书架](#)
- ▶ [加入引用管理器](#)

复制索引

Email Alert

文章反馈

浏览反馈信息

相关信息

▶ [本刊中 包含“肝”的 相关文章](#)

▶ 本文作者相关文章

- [李家平](#)
- [周奇](#)
- [王海林](#)
- [谭国胜](#)
- [陈伟](#)
- [杨建勇](#)

value of hepatic arterial perfusion (HAP), portal vein perfusion (PVP) and total liver perfusion (TLP) among groups were compared. The impacts of Lipo-PGE₁ on liver haemodynamics at different time were investigated. Twenty-four health dogs were randomly divided into four groups: control group, peripheral vein group, hepatic artery group and superior mesenteric artery group. Liver CTPI was performed at 5 min after 1 μg/kg Lipo-PGE₁ administration in those groups. The values of HAP, PVP and TLP were compared and effects of Lipo-PGE₁ on liver blood flow by different medication were observed.

RESULTS: The values of liver perfusion (mL · min⁻¹ · mL⁻¹) at 0, 5, 15 and 30 min after 1 μg/kg Lipo-PGE₁ administration via vein were as follows: HAP: 0.22 ± 0.65, 0.24 ± 0.65, 0.22 ± 0.69, 0.22 ± 0.06; PVP: 1.22 ± 0.40, 1.88 ± 0.59, 1.55 ± 0.55, 1.29 ± 0.57; TLP: 1.44 ± 0.42, 2.12 ± 0.61, 1.77 ± 0.56, 1.51 ± 0.58, respectively. No significant difference in HAP among groups was observed, but in PVP and TLP, significant differences (F=3.812, P<0.05; F=3.805, P<0.05) among groups were found. The values of PVP and TLP were most obviously increased at 5 min, and the values of PVP and TLP were still on the high level at 15 min and 30 min. The values of liver perfusion (mL · min⁻¹ · mL⁻¹) by different medication were as follows: HAP: 0.22 ± 0.06, 0.24 ± 0.06, 0.31 ± 0.07, 0.26 ± 0.05; PVP: 1.28 ± 0.38, 2.33 ± 0.41, 2.37 ± 0.55, 2.83 ± 0.94; TLP: 1.50 ± 0.40, 2.57 ± 0.42, 2.67 ± 0.58, 3.09 ± 0.94, respectively. No significant difference in HAP among groups (F=2.248, P>0.05) was found, but in PVP and TLP group, significant differences (F=6.892, P<0.01; F=7.802, P<0.01) among groups were observed. In addition, superior mesenteric artery group showed higher value of PVP and TLP than other methods.

CONCLUSION: Lipo-PGE₁ obviously increases liver blood perfusion, especially for portal vein perfusion. Interventional technology provides an effective pathway to improve hepatic perfusion.

Key words [Liver](#) [Perfusion](#) [Alprostadil](#) [Interventional technology](#) [Liposome prostaglandin E1](#)

DOI: 1000-4718

通讯作者 杨建勇 jpli3s@medmail.com.cn